Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.
BMC Gastroenterol. 2011 May 19;11:56. doi: 10.1186/1471-230X-11-56.
Gastric hepatoid adenocarcinoma (HAC) is a special type of gastric cancer that morphologically mimics hepatocellular carcinoma. In this study, we performed an evaluation of clinicopathologic characteristics, treatment outcome, and prognosis in patients with gastric HAC.
We consecutively enrolled patients with pathologically proven gastric HAC at Seoul National University Hospital between January 1996 and December 2008 and conducted a retrospective review. Among 15,253 patients with gastric cancer, 26 patients (0.17%) were diagnosed as gastric HAC.
Among 26 patients, 22 were male and the median age was 63. Stage at diagnosis was stage IB in 3 patients, stage II in 6 patients, stage III in 7 patients, and stage IV in 10 patients. Eight patients out of 18 patients with stage IB, II, III, and IV relapsed after curative surgery. Relapse-free survival for these patients was 16.67 months. The most common metastatic site was intraabdominal lymph nodes (n = 9), followed by the liver (n = 8). Thirteen patients received palliative chemotherapy. The most commonly used regimen was a combination of fluoropyrimidine and platinum. Partial response was observed in one patient and stable disease in 5 patients. Median overall survival and progression free survival of these patients were 8.03 (95% CI: 6.59-9.47) and 3.47 months (95% CI: 0.65-6.29), respectively.
Gastric HAC is a very rare but unique type of stomach cancer. Early detection of this type of cancer is of critical importance to patient prognosis. Additional studies to reveal the biology of this tumor are warranted.
胃肝样腺癌（HAC）是一种形态上模仿肝细胞癌的特殊类型胃癌。在本研究中，我们评估了胃 HAC 患者的临床病理特征、治疗结果和预后。
我们连续纳入了 1996 年 1 月至 2008 年 12 月在首尔国立大学医院经病理证实的胃 HAC 患者，并进行了回顾性复习。在 15253 例胃癌患者中，有 26 例（0.17%）被诊断为胃 HAC。
在 26 例患者中，22 例为男性，中位年龄为 63 岁。诊断时分期为 IB 期 3 例，II 期 6 例，III 期 7 例，IV 期 10 例。18 例 IB、II、III 和 IV 期患者中有 8 例在根治性手术后复发。这些患者的无复发生存期为 16.67 个月。最常见的转移部位是腹腔淋巴结（n=9），其次是肝脏（n=8）。13 例患者接受姑息化疗。最常用的方案是氟嘧啶和铂类联合方案。1 例患者部分缓解，5 例患者疾病稳定。这些患者的中位总生存期和无进展生存期分别为 8.03（95%CI：6.59-9.47）和 3.47 个月（95%CI：0.65-6.29）。
胃 HAC 是一种非常罕见但独特的胃癌类型。早期发现这种类型的癌症对患者的预后至关重要。需要进一步研究以揭示这种肿瘤的生物学特性。
